Abraxis Bioscience, LLC

Autotelic, LLC

Other

Nantbioscience, Inc.

Vuong Trieu

Neil P Desai

Patrick Soon-Shiong

Chunlin Tao

Tapas De

Xiping Liu

Daniel Knauer

Sherry Xiaopei Ci

Andrew Yang

Qinwei Wang

Osmond D'Cruz

Chengzhi Yu

Cheng Zhi Yu

Qiang Yao

Chulho Park

Tapas K De

Cheng-Zhi Yu

Bridget Beals Grim

Soon-Shiong Patrick

The invention provides compositions comprising SPARC binding ScFv and its use.

SPARC binding ScFvs

This disclosure provides compositions, including antibodies or fragments or derivatives thereof, and related devices and methods effective for detecting and quantifying olmesartan in a sample. The compositions, devices, and methods can be applied to improve the effectiveness of hypertension therapy by monitoring a subject's compliance by determining one or more pharmacokinetic parameters of the subject with a point-of-care device after antihypertensive drug administration. In one embodiment, the antihypertensive drug is olmesartan and the pharmacokinetic parameter is AUC.

Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension

Optimized affinity reagent compositions for binding paclitaxel, such as antibodies, antibody fragments, and antibody derivatives, related methods of use, and related kits, are provided herein. Affinity reagents that comprise one or more complementary determining regions (CDRs) optimized from anti-paclitaxel antibodies antibody 8A10 and 3C6 are specifically provided. The disclosed affinity reagents are useful for binding and detecting paclitaxel in a sample, such as for determining or optimizing future doses of paclitaxel in a subject that was previously administered with paclitaxel.

Antibody-based affinity reagents for binding paclitaxel

Provided herein are composition for sensitizing tumors to anti-tumor therapies. The compositions include antisense oligonucleotides against TGF&#x3b2;2, wherein the compositions sensitize tumors to anti-tumor therapies. Also provided herein are method for treating cancer using the compositions described herein.

Compositions and methods for treating pancreatic cancer

Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.

Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods

Methods, devices, reagent, systems and kits for the detection, diagnosis of ovarian cancer as well as for the monitoring of ovarian cancer progression and for monitoring the progress of ovarian cancer treatments using BNP as a biomarker.

Methods and compositions for personalized medicine by point-of-care devices for brain natriuretic peptide

The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.

SPARC and methods of use thereof

The invention provides compositions comprising SPARC binding ScFc and its use.

SPARC binding ScFcs

The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy.

Use of the SPARC microenvironment signature in the treatment of cancer

The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors.

SPARC binding antibodies and uses thereof

The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy.

Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

Growing community of inventors

Agoura Hills, CA, United States of America

Vuong Trieu